Financial Performance - For the year ended December 31, 2023, the company reported total revenue of HKD 961,291,000, a decrease of 51.0% compared to HKD 1,961,704,000 in the previous year[2] - The cost of sales for the year was HKD 996,894,000, resulting in a gross loss of HKD 35,603,000, compared to a gross profit of HKD 76,482,000 in the previous year[2] - The net loss attributable to the owners of the company for the year was HKD 52,705,000, significantly improved from a loss of HKD 233,703,000 in the previous year, representing a reduction of 77.5%[2] - The basic and diluted loss per share for the year was HKD 3.11, compared to HKD 13.79 in the previous year[2] - The group reported a loss before tax of HKD 52.705 million for the year ended December 31, 2023, compared to a loss of HKD 233.703 million in 2022[24] - The group recognized other income of HKD 69, down from HKD 452 in 2022, indicating a decline of about 84.7%[29] - The group had a net loss from other (losses)/gains of HKD 548 in 2023, compared to a net loss of HKD 308.176 million in 2022, showing a significant improvement[30] - The company recorded a loss attributable to shareholders of approximately HKD 52.7 million for the year, compared to a loss of approximately HKD 233.7 million in the previous year[58] Assets and Equity - Total assets decreased to HKD 478,117,000 from HKD 534,434,000, a decline of 10.5% year-over-year[5] - Total equity attributable to the owners of the company decreased to HKD 384,114,000 from HKD 436,705,000, a decrease of 12.0%[5] - Non-current assets in Hong Kong decreased to HKD 26.465 million in 2023 from HKD 28.898 million in 2022, a decline of approximately 8.4%[27] - As of December 31, 2023, the company's total assets were approximately HKD 478.1 million, down from approximately HKD 534.4 million in 2022[62] Liquidity and Cash Flow - Cash and cash equivalents increased significantly to HKD 19,525,000 from HKD 1,642,000, indicating improved liquidity[5] - The current ratio as of December 31, 2023, was approximately 4.8 times, compared to 5.2 times in 2022[62] - The company’s cash and cash equivalents were approximately HKD 19.5 million as of December 31, 2023, compared to approximately HKD 1.6 million in 2022[68] - The company has no borrowings as of December 31, 2023[69] Revenue Breakdown - Revenue from health products was HKD 7.157 million, down from HKD 9.482 million in 2022, a decrease of about 24.5%[22] - Revenue from electronic components was HKD 954.134 million, down from HKD 1,952.222 million in 2022, a decrease of approximately 51.1%[22] - Health product sales generated only about HKD 7.2 million in revenue for the year, indicating a focus shift towards the electronic components business[55] - Revenue from the electronic components business decreased by approximately 51.1% to about HKD 954.1 million in 2023, down from HKD 1,952.2 million in the previous year[53] Inventory and Receivables - Inventory decreased to HKD 329,785,000 from HKD 380,461,000, a reduction of 13.3%[5] - Trade and other receivables totaled HKD 102.3 million in 2023, a decrease from HKD 123.4 million in 2022, reflecting a decline of about 17.1%[41] - The company’s trade receivables aged 91 to 180 days were zero in 2023, down from HKD 2.53 million in 2022[44] - The company has no trade receivables as of December 31, 2023, and wrote off bad debts of approximately HKD 2.5 million during the year[67] Corporate Governance and Future Plans - The company is committed to high standards of corporate governance to protect shareholder interests and enhance corporate value[80] - The company plans to invest in factories in China to provide additional value-added services, including support, modification, assembly, packaging, and testing services[60] - The company aims to expand its product portfolio and improve profitability by obtaining additional distribution rights from upstream manufacturers[60] Dividends and Shareholder Information - The company did not declare any dividends for the years ended December 31, 2023, and December 31, 2022[40] - The board of directors does not recommend a final dividend for the year, consistent with the previous year[77] - The annual general meeting is scheduled for June 20, 2024, with a suspension of share transfer registration from June 17 to June 20, 2024[85] - The annual performance announcement will be published on the stock exchange and the company's website, with a full annual report to be sent to shareholders[86] Legal and Compliance - The company is facing a legal claim from a supplier for approximately CAD 2.8 million (approximately HKD 16.8 million), but management believes the claim lacks evidence and does not expect a significant adverse impact on the overall financial position[72] - The audit committee, consisting of three independent non-executive directors, reviewed the financial statements and confirmed compliance with applicable accounting standards[82]

Financial Performance - The semiconductor business revenue decreased by approximately 71.9% to about HKD 337.2 million compared to the previous period's revenue of approximately HKD 1,201.3 million[8]. - Revenue for the six months ended June 30, 2023, was HKD 339,899,000, a decrease of 71.7% compared to HKD 1,201,279,000 for the same period in 2022[50]. - The company recorded a loss attributable to shareholders of approximately HKD 112.1 million for the interim period, compared to a profit of approximately HKD 19.6 million in the previous period[19]. - The company reported a pre-tax loss of HKD 112,118,000 for the six months ended June 30, 2023, compared to a profit of HKD 19,608,000 in the same period of 2022[82]. - The company recorded a total comprehensive loss of HKD 112,118,000 for the six months ended June 30, 2023, compared to a loss of HKD 19,608,000 in the same period of 2022[56]. - Basic loss per share for the period was HKD 0.0662, compared to earnings of HKD 0.0116 per share in the previous year[50]. - The company did not recommend the payment of an interim dividend for the interim period[27]. Assets and Liabilities - Total assets as of June 30, 2023, were approximately HKD 417.5 million, a decrease from approximately HKD 534.4 million as of December 31, 2022[20]. - Current assets decreased to HKD 389,791,000 from HKD 505,536,000, a decline of 23%[52]. - The total equity attributable to the owners of the company was HKD 324,605,000, down from HKD 436,705,000, reflecting a decrease of 25.7%[52]. - As of June 30, 2023, total liabilities decreased to HKD 92,868,000 from HKD 97,729,000, representing a reduction of approximately 5.4% year-over-year[54]. - The company has a low debt-to-asset ratio of approximately 4.5% as of June 30, 2023, compared to 5.5% as of December 31, 2022[20]. - The company recorded an expected credit loss provision of HKD (2,530,000) for the first half of 2023, with inventory provisions amounting to HKD (113,405,000)[70]. Inventory and Cash Flow - The group recorded an inventory provision of approximately HKD 113.4 million during the interim period, which was not present in the previous period[15]. - Inventory decreased by approximately 28.3% from about HKD 380.5 million (net of inventory provisions) as of December 31, 2022, to about HKD 272.6 million as of June 30, 2023[21]. - Cash and cash equivalents at the end of the period were HKD 9,165,000, down from HKD 163,428,000 at the end of June 2022, indicating a decrease of approximately 94.4%[58]. - The company reported a net cash inflow from operating activities of HKD 7,895,000 for the six months ended June 30, 2023, a significant decline from HKD 168,515,000 in the same period last year[58]. Business Strategy and Market Outlook - The group plans to invest in factories in China to provide additional value-added services, including support, modification, assembly, packaging, and testing services[12]. - The group is exploring potential investments in food processing and raw material extraction factories in Taiwan and China to expand its health business[12]. - The group aims to diversify its product range and customer base while monitoring market conditions to maintain a strong competitive advantage[13]. - The group anticipates that the semiconductor market will continue to expand in the coming years due to rising demand from renewable energy and electric vehicles[12]. - The health business is actively tracking market demand and supply trends to optimize its product portfolio and business strategy[9]. - Future outlook remains uncertain due to the significant losses and reduced cash flow, which may impact market expansion strategies[60]. Shareholder Information - As of June 30, 2023, the company has a total of 1,694,450,000 shares issued[40]. - Major shareholder 拓陞 holds 892,485,771 shares, representing 52.67% of the total shares[35]. - The company has a significant concentration of ownership, with major shareholders holding over 50% of the shares[35]. - The company has a stock option plan that allows for the issuance of options up to 30% of the total issued shares at any time[39]. - The stock option plan was adopted on June 9, 2014, and will expire on June 8, 2024[39]. - The company has no knowledge of any other individuals holding 5% or more of the shares as of June 30, 2023[38]. Operational Challenges - The semiconductor segment recorded a gross loss of approximately HKD 6.4 million, down from a gross profit of approximately HKD 28.2 million in the previous period[14]. - The health business generated only about HKD 2.7 million in revenue during the interim period due to the adverse effects of the COVID-19 pandemic[9]. - The company will continue to attract new customers to expand its customer base despite ongoing market challenges in the semiconductor industry[18]. - The company has not reported any new product launches or technological advancements during this period[60]. - The company continues to focus on its core business segments: electronic components and health products, with no mention of mergers or acquisitions in the current report[66].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Qianhai Health Holdings Limited 前 海 健 康 控 股 有 限 公司 （於開曼群島註冊成立的有限公司） 911 （股份代號： ） 截至二零二三年六月三十日止六個月的 中期業績公告 前海健康控股有限公司（「本公司」）董事（「董事」）會（「董事會」）欣然宣佈本公司及其 附屬公司（「本集團」）截至二零二三年六月三十日止六個月（「本中期期間」）的未經審 核簡明綜合中期業績，連同截至二零二二年六月三十日止同期（「上一期間」）的比較 數字如下： 簡明綜合損益及其他全面收益表 截至二零二三年六月三十日止六個月 截至六月三十日止六個月 二零二三年 二零二二年 附註 千港元 千港元 ...

Financial Performance - The company reported a revenue of HKD 1,961,704,000 for 2022, a significant increase of approximately 592.2% compared to HKD 283,398,000 in 2021[6] - Gross profit for the year was HKD 76,482,000, up from HKD 16,038,000 in the previous year[6] - The company experienced an operating loss of HKD 233,703,000, compared to a loss of HKD 888,000 in 2021[6] - The net asset value per share decreased to HKD 0.26 from HKD 0.40 in the previous year[6] - The company recorded a net loss attributable to shareholders of approximately HKD 233.7 million, compared to a loss of about HKD 0.9 million in the previous year[24] - The total reserves available for distribution to shareholders as of December 31, 2022, amounted to approximately HKD 356,564,000, down from HKD 546,407,000 in 2021[122] - The company did not recommend any dividend payment for the year, consistent with the previous year[119] Inventory and Supply Chain - The company holds inventory valued at approximately HKD 1,876,000,000, with over 98% consisting of semiconductor materials[10] - Inventory value as of December 31, 2022, was approximately HKD 380.5 million, a decrease of about 16.4% from approximately HKD 455.1 million a year earlier[26] - The company recorded an inventory provision of approximately HKD 238.0 million due to a decline in semiconductor market prices exceeding 30% in the last quarter of the year[21] - The semiconductor industry faced significant price declines in the second half of 2022, with prices dropping over 20% to 30% in the last quarter[10] - The company aims to optimize its product mix in response to weakening market demand[11] - The company has established a main purchase agreement with a major supplier in China to secure a stable supply of electronic components[9] Business Expansion and Strategy - The health business generated only HKD 9,500,000 in revenue, accounting for approximately 0.5% of total revenue[13] - The company is exploring potential collaborations with well-known online and offline retail platforms in Hong Kong and China to expand its health product offerings[14] - The company plans to establish subsidiaries in China and Taiwan to expand its business coverage and explore potential investments in food processing and raw material extraction factories[15] - The company aims to enhance its product portfolio by sourcing high-quality new products from manufacturers in China, Taiwan, and Thailand, and plans to invest in factories in China to provide additional value-added services[17] Corporate Governance - The company is committed to high standards of corporate governance, adhering to the principles of the Corporate Governance Code as per the listing rules[48] - The board consists of a total of eight directors, including four non-executive directors, one executive director, and three independent non-executive directors[51] - The company emphasizes the importance of a diverse board composition, considering factors such as gender, age, ethnicity, and professional experience in its diversity policy[56] - The company has established a mechanism to ensure independent viewpoints are obtained in board decisions, encouraging active participation from independent non-executive directors[55] - The company has implemented a robust internal control system to ensure effective monitoring and checks and balances[48] Risk Management - The group faces major risks including credit risk, currency risk, and liquidity risk as of December 31, 2022[176] - The board has established a robust risk management and internal control system to minimize procurement price risks and protect the group's assets[92] - The risk management and internal control measures are deemed effective in assessing and managing overall procurement price risks[92] - The audit committee reviews the effectiveness of the risk management and internal control systems annually, ensuring sufficient resources and staff qualifications in accounting and financial reporting[93] Employee and Stakeholder Engagement - The group provides various employee benefits, including mandatory provident fund, medical insurance, and performance-based discretionary bonuses[175] - The group recognizes the importance of stakeholder engagement for its success and has conducted a materiality assessment to understand key concerns[182] - The group has established effective internal control systems to enhance operational efficiency and deliver environmental and social benefits to stakeholders[186] Environmental Responsibility - The company is committed to sustainable development and has implemented waste recycling initiatives in its operations[170] - The company's direct carbon emissions for the year were 2.77 tons, a decrease of 79.5% from 13.49 tons in the previous year[189] - Indirect carbon emissions amounted to 22.29 tons, down 8.7% from 24.41 tons in the previous year[189] - Total energy consumption was 34,203 kWh, a reduction of 7.1% from 36,808 kWh in the previous year[194] - The company is committed to implementing energy-saving strategies and educating employees on environmental awareness[193] Shareholder Information - The issued share capital of the company remained unchanged during the year[120] - As of December 31, 2022, the directors and the CEO held a total of 892,485,771 shares, representing 52.67% of the company's equity[142] - The company has a share option plan approved by shareholders on June 9, 2014, aimed at rewarding selected participants for their contributions[152] - The maximum number of shares available for issuance under the plan is 170,040,500 shares, representing 10% of the issued ordinary share capital as of June 13, 2017[155]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或任何部 分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Qianhai Health Holdings Limited 前 海 健 康 控 股 有 限 公司 （於開曼群島註冊成立的有限公司） 911 （股份代號： ） 截至二零二二年十二月三十一日止年度的 年度業績公告 前海健康控股有限公司（「本公司」）董事（「董事」）會（「董事會」）欣然宣佈本公司及其 附屬公司（「本集團」）截至二零二二年十二月三十一日止年度（「本年度」）的經審核綜 合業績，連同截至二零二一年十二月三十一日止年度同期（「上一年度」）的比較數字 如下： 綜合損益表 截至二零二二年十二月三十一日止年度 二零二二年 二零二一年 附註 千港元 千港元 3 1,961,704 283,398 收益 4 (1,885,222) (267,360) 銷售成本 76,482 16,038 毛利 ...

Business Focus Shift - The company plans to shift its focus and resources from the health business to the electronic components business due to higher performance and growth potential in the latter[7]. - The health business primarily involves the procurement and wholesale of health products, including ginseng and skincare products, supported by a professional team with over 10 years of experience[10]. - The company is actively exploring potential collaborations with a major online retail platform in China to supply health products, which may enhance brand promotion and business outreach[13]. Electronic Components Business - The electronic components business was launched in July 2019, following a significant acquisition by the chairman, which has since established a global trading network for electronic components[3]. - The sales team has over 20 years of experience in the electronic components industry, enabling the company to procure high-quality products at reasonable prices[4]. - The company has established long-term relationships with over 20 customers and suppliers, primarily in the electronic components sector[4]. - The company plans to recruit more engineers and sales personnel to support the growth of the electronic components business[8]. - The company aims to expand its electronic components business through various strategies outlined in its mid-year report[8]. - The sales team regularly communicates with suppliers and customers to stay updated on market trends and demand[5]. Health Business Relationships - The health business maintains stable relationships with over 10 suppliers and customers, primarily in Hong Kong and China[11]. - The company is conducting site visits to manufacturers in Taiwan and Thailand to explore procurement of new health products and establish authorized distribution relationships[17]. Financial Prepayments - As of February 28, 2022, the total prepayment made to Jingdong E-Commerce was approximately HKD 60.5 million, representing about 8.0% of the company's total assets[20]. - By March 9, 2022, the total prepayment increased to approximately HKD 84.0 million, accounting for about 11.2% of total assets, reflecting a 3.2% increase[20]. - On March 22, 2022, the prepayment rose to approximately HKD 106.7 million, which was about 14.2% of total assets, showing a 3.0% increase[20]. - By March 25, 2022, the prepayment reached approximately HKD 169.1 million, representing about 22.5% of total assets, with an 8.3% increase from the previous amount[20]. - As of June 8, 2022, the prepayment totaled approximately HKD 212.4 million, accounting for about 28.8% of total assets, indicating a 6.3% increase[20]. - On June 17, 2022, the prepayment further increased to approximately HKD 245.0 million, which was about 33.2% of total assets, reflecting a 4.4% increase[22]. - By July 14, 2022, the prepayment reached approximately HKD 272.0 million, representing about 36.8% of total assets, with a 3.6% increase[22]. Investment Opportunities - The company is in discussions for a potential investment opportunity in a food processing and raw material extraction factory in Taiwan, aimed at creating synergies and gaining deeper market insights[14][16]. - The company will continue to review its business activities and assets to create greater value for shareholders[7].

Financial Performance - The total revenue for the interim period was approximately HKD 1,201.3 million, a significant increase from approximately HKD 195.7 million in the previous period, representing a growth of about 514%[8] - Gross profit for the interim period was approximately HKD 28.2 million, compared to HKD 10.6 million in the previous period, indicating a growth of approximately 166%[8] - Operating profit for the interim period was approximately HKD 19.6 million, a turnaround from an operating loss of approximately HKD 3.7 million in the previous period[8] - Net profit for the interim period was approximately HKD 19.6 million, compared to a net loss of approximately HKD 3.7 million in the previous period, marking a significant recovery[8] - Basic earnings per share for the interim period were approximately HKD 1.16, compared to a loss per share of approximately HKD 0.22 in the previous period[8] - The electronic components business generated revenue of approximately HKD 1,201.3 million, a significant increase from HKD 97.6 million in the previous period, with a segment profit of approximately HKD 28.2 million compared to HKD 12.0 million previously[14] - The gross profit for the same period was HKD 28,162,000, compared to HKD 10,559,000 in 2021, indicating a gross margin improvement[48] - The operating profit before tax for the period was HKD 19,608,000, a turnaround from a loss of HKD 3,715,000 in the previous year[48] - The company reported a net profit attributable to shareholders of HKD 19,608,000, compared to a loss of HKD 3,715,000 in the prior year[48] Business Focus and Strategy - The increase in revenue was primarily driven by higher sales volumes in the electronic components business, which is the sole contributor to total revenue during the interim period[10] - The company has shifted its focus and resources from the health business to the electronic components business to maximize shareholder profits[10] - The health business experienced a decline due to the impact of COVID-19 on consumer behavior and spending in China, leading to reduced demand for health products[10] - The company continues to actively develop its health business and diversify its product offerings despite the challenges faced[10] - The company is focused on expanding its product lines in electronic components and health products, although specific new products or technologies were not detailed in the report[65] Financial Position and Liquidity - The current ratio as of June 30, 2022, was approximately 23.8 times, up from 10.1 times on December 31, 2021[17] - Inventory decreased by approximately 39.2% to about HKD 276.9 million from HKD 455.1 million as of December 31, 2021, primarily due to reduced inventory turnover[17] - Cash and cash equivalents were approximately HKD 163.4 million as of June 30, 2022, compared to HKD 2.5 million on December 31, 2021[21] - The company had no bank borrowings as of June 30, 2022, down from HKD 7,165,000 at the end of 2021[52] - The cash and cash equivalents increased significantly to HKD 163,428,000 from HKD 2,470,000 at the end of 2021, indicating improved liquidity[50] - The net cash generated from operating activities for the six months ended June 30, 2022, was HKD 168,515,000, compared to a net cash used of HKD 7,014,000 in the same period last year[56] Shareholder Information - As of June 30, 2022, the total number of issued shares was 1,694,450,000[31] - The beneficial ownership of shares by Tak Sing Limited was 892,485,771, representing 52.67% of the total shares[34] - Beneficial owners Huang Guanchao and Lin Jie hold 80% and 10% of Tak Sing Limited, respectively[35] - The company has a stock option plan that allows for the issuance of options up to 30% of the total issued shares at any time, with a limit of 1% for any individual participant within a 12-month period[38] - The stock option plan was adopted on June 9, 2014, and is set to expire on June 8, 2024[38] - No directors or the CEO held any interests in the company's shares or related securities that required disclosure as of June 30, 2022[37] Dividend and Shareholder Returns - The company does not recommend the payment of an interim dividend for the period[25] - The company did not declare any dividends for the six months ended June 30, 2022[78] Other Financial Metrics - Total liabilities decreased from HKD 68,093,000 to HKD 28,179,000, representing a reduction of approximately 58.6%[52] - The company's total equity increased to HKD 690,141,000 from HKD 670,533,000 at the end of 2021, reflecting a growth of approximately 2.3%[50] - The company faced foreign exchange risks, reporting foreign exchange gains of approximately HKD 1.5 million during the period, down from HKD 1.8 million previously[23] - The financing costs for the first half of 2022 were significantly reduced to HKD 16 from HKD 275 in the same period of 2021[71] - The company had unexercised share options totaling 52,465,000 shares as of June 30, 2022[41] - The total trade and other receivables as of June 30, 2022, amounted to HKD 249,140, a slight decrease from HKD 250,988 as of December 31, 2021[83] - Trade payables decreased from HKD 50,439 thousand in December 2021 to HKD 21,587 thousand in June 2022, representing a decline of 57.3%[89] - Other payables, including accrued expenses, decreased from HKD 3,609 thousand in December 2021 to HKD 1,130 thousand in June 2022, a reduction of 68.7%[89] - Total trade and other payables decreased from HKD 54,262 thousand in December 2021 to HKD 22,931 thousand in June 2022, reflecting a decrease of 57.8%[89]

Financial Performance - The company's revenue for the year ended December 31, 2021, was HKD 283.4 million, a decrease of 62.7% compared to HKD 760.7 million in 2020[6]. - The gross profit for the year was HKD 16.0 million, down 64.5% from HKD 45.1 million in the previous year, with a gross margin of 5.7% compared to 5.9% in 2020[14]. - The health business generated revenue of approximately HKD 98.1 million, a decline of about 77.9% year-on-year, while the electronic components business contributed HKD 185.3 million, accounting for 65.4% of total revenue[10][12]. - The company recorded a loss attributable to owners of approximately HKD 0.9 million for the year, compared to a loss of HKD 0.8 million in the previous year[16]. - The electronic components business had a gross margin of 7.7%, significantly higher than the health business's gross margin of 1.8%[10]. Asset and Liability Management - Total assets at the end of the year were HKD 738.6 million, slightly up from HKD 735.5 million in 2020, while total liabilities increased to HKD 68.1 million from HKD 62.3 million[6]. - Non-current assets decreased by approximately 73.4% to about HKD 48.1 million as of December 31, 2021, primarily due to the sale of a subsidiary[20]. - Current assets totaled approximately HKD 690.5 million, an increase from HKD 554.8 million in 2020, while current liabilities rose to about HKD 68.1 million from HKD 61.6 million[20]. - The current ratio improved to approximately 10.1 times as of December 31, 2021, compared to 9.0 times in 2020[20]. - Inventory value increased by approximately 39.4% to HKD 455.1 million from HKD 326.4 million in 2020[20]. Strategic Initiatives - The company plans to continue monitoring market conditions and diversify its product range and customer base to maintain a competitive advantage[9]. - The company aims to maximize shareholder profits by focusing on the electronic components business, which has shown better profitability compared to the health business[8]. - The company plans to continue exploring opportunities to diversify its product portfolio and expand revenue sources in the future[18]. - The company emphasized that the divestiture allows for a more focused investment in core business areas, enhancing asset returns amid a sluggish real estate market[32]. Corporate Governance - The company has a strong management team with over 30 years of experience in finance and accounting, led by the Chief Financial Officer who is a senior member of multiple accounting associations[45]. - The company has implemented a robust internal control system to enhance corporate governance and protect shareholder interests[55]. - The board consists of a total of ten directors, including four non-executive directors, three executive directors, and three independent non-executive directors, ensuring a balanced decision-making process[58]. - The company is committed to adhering to the corporate governance code as outlined in the listing rules, demonstrating its dedication to accountability and transparency[55]. - The audit committee's main responsibilities include providing independent opinions on the effectiveness of the group's financial reporting procedures and internal controls[74]. Shareholder Information - The total reserves available for distribution to shareholders as of December 31, 2021, amounted to approximately HKD 546,407,000, a slight decrease from HKD 550,976,000 in 2020[119]. - The company did not recommend any dividend payment for the year, consistent with the previous year[116]. - The company has adopted a dividend policy on January 1, 2021, allowing shareholders to share in profits while retaining sufficient reserves for future development[96]. Environmental Responsibility - The company plans to continue enhancing resource efficiency and applying green technologies to minimize environmental impact[165]. - The company reported direct carbon emissions of 13.49 tons and indirect emissions of 24.41 tons for the year, compared to 7.57 tons and 34.5 tons respectively in the previous year[188]. - The company aims to reduce carbon emissions by encouraging the use of teleconferencing and minimizing business travel in the coming years[189]. - The company has established a collection area for recyclable materials, including paper, plastic, and metal, to enhance waste recycling efforts[190]. - The company is committed to complying with all relevant environmental laws and regulations applicable to its business operations[185]. Risk Management - The main risks and uncertainties faced by the group include credit risk, currency risk, and liquidity risk as of December 31, 2021[172]. - The group has implemented appropriate internal controls and quality control measures to ensure compliance with the Sale of Goods Ordinance in Hong Kong[169]. - The company has not experienced any violations of laws and regulations that had a significant impact on the group during the year[170].

Qianhai Health Holdings Limited 前海健康控股有限 公 司 （股份代號: 911） （於開曼群島註冊成立之有限公司） 中期報告 2021 (Stock Code: 911) Qianhai Health Holdings Limited 前海健康控股有限 公 司 (Incorporated in the Cayman Islands with limited liability) Interim Report 2021 目錄 | 公司資料 | 2 | | --- | --- | | 管理層討論與分析 | 3 | | 企業管治及其他資料 | 6 | | 簡明綜合損益及其他全面收益表 | 12 | | 簡明綜合財務狀況表 | 13 | | 簡明綜合權益變動表 | 15 | | 簡明綜合現金流量表 | 16 | | 綜合財務報表附註 | 17 | 1 前海健康控股有限公司 • 二零二一年中期報告 目錄 公司資料 董事會 非執行董事 黃冠超先生 （主席） 林捷先生 陳凱犇先生 （委任自二零二一年九月三日起生效） 陳琦先生 （委任自二零二一年九月三日起生效） 執行董事 許克立先生 藍顯賜先 ...

（於開曼群島註冊成立之有限公司） （股份代號: 911） 年 報 2020 前海健康控股有限 公 司 Qianhai Health Holdings Limited ( S t o c k C o d e : 9 1 1 ) 前海健康控股有限 公 司 Islands with limited liability) Qianhai Health Holdings Limited ANNUAL REPORT 2020 前海健康控股有限 公 司 Qianhai Health Holdings Limited ANNUAL (Incorporated in the Cayman | 公司資料 | 2 | | --- | --- | | 財務摘要 | 3 | | 管理層討論與分析 | 4-7 | | 董事及高級管理層之履歷詳情 | 8-10 | | 企業管治及其他資料 | 11-21 | | 董事會報告 | 22-35 | | 環境、社會及管治報告 | 36-44 | | 獨立核數師報告 | 45-50 | | 綜合損益表 | 51 | | 綜合全面收益表 | 52 | | 綜合財務狀況表 | 53-54 | | 綜合 ...